Nantes, France, April 10, 2024, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that the Company has received non-dilutive financing of 8.4 million euros as part of the the “i-Demo” call for projects from the France 2030 plan operated by Bpifrance on behalf of the State, the objective of which is the development of industrial and service companies in growing markets, creating value and competitiveness for our economy and contributing to the energy, ecological and digital transitions. This support applies from the technical feasibility study to marketing.